| REVIEW ARTICLE |
|
| Year : 2020 | Volume
: 4
| Issue : 5 | Page : 6-9 |
|
|
High-Flow Nasal Cannula for Patients with COVID-19 Acute Hypoxemic Respiratory Failure
Hassan M Alshaqaq1, Zohair A Al Aseri2, Mohammed Saeed Alshahrani3
1 College of Medicine, Imam Abdulrahman bin Faisal University, Dammam, Saudi Arabia
2 Department of Emergency Medicine and Critical Care, College of Medicine, King Saud University, Riyadh; Adult Critical Care Services, Ministry of Health, Dammam, Saudi Arabia
3 Department of Emergency and Critical Care Medicine, King Fahd Hospital of the University, Imam Abdulrahman bin Faisal University, Dammam, Saudi Arabia
Correspondence Address:
Mohammed Saeed Alshahrani
Department of Emergency and Critical Care Medicine, King Fahad Hospital of the University, Imam Abdulrahman Bin Faisal University, PO Box 40236, Dammam 31952
Saudi Arabia
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/sccj.sccj_42_20
|
|
|
High-flow nasal cannula (HFNC) is a noninvasive oxygenation modality that delivers heated and humidified oxygen. It possesses several advantages due to the unique physiological effects on the lung and ventilation mechanics compared to other modes of oxygen therapy. The use of HFNC is tolerable, comfortable, and easy to set up. Current evidence indicates that the use of HFNC in critically ill patients with coronavirus disease 2019 (COVID-19)-acute hypoxemic respiratory failure (AHRF) is noninferior to noninvasive ventilation in the reduction of endotracheal intubation rate. Early identification of HFNC failure is vital to avoid delaying intubation. However, multiple knowledge gaps exist, and unpowered observational studies limit HFNC incorporation into strong recommendations. The low dispersion of particles demonstrates the feasibility of HFNC; yet, an appropriate setting and precautions should be maximized. Here, we review the recent evidence of HFNC implications in the management of patients with COVID-19-AHRF.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
